Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Evaluation of clinical practice regarding SGLT2 inhibitor use in patients with type 2 diabetes mellitus and established coronary artery disease in James Cook University Hospital

Ching Khai Ho, Andrew Turley and Mark Hammonds
Download PDF
DOI: https://doi.org/10.7861/clinmed.22-4-s88
Clin Med July 2022
Ching Khai Ho
ARoyal Victoria Infirmary, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Turley
BSouth Tees Hospital NHS Foundation Trust, Middlesbrough, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Hammonds
BSouth Tees Hospital NHS Foundation Trust, Middlesbrough, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Introduction

Type 2 diabetes mellitus (T2DM) is a significiant risk factor for coronary artery disease (CAD). The landmark EMPA-REG trial demonstrated that SGLT2 inhibition significantly decreased the risk of all-cause mortality (number needed to treat: 39 at 3.1 years) in patients with T2DM and CAD.1

In a previous audit, we showed that six out of 259 (2.3%) diabetic patients were prescribed gliflozin on discharge. Therefore, a clinical protocol on SGLT2 inhibitor commencement (Fig 1) has been in place at James Cook University Hospital coronary care unit for all T2DM patients who present with an acute coronary syndrome (ACS; ST segment elevation myocardial infarction or non-ST segment elevation myocardial infarction). This protocol is in line with the national CaReMe intiative endorsed by the British Cardiovascular Society.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Protocol for commencing empagliflozin (SGLT2 inhibitor) in patients with type 2 diabetes mellitus and confirmed voronary artery disease.

Objective

To evaluate whether T2DM patients admitted with ACS are commenced on SGLT2 inhibitor prior to hospital discharge.

Methods

Data were collected retrospectively from the validated Myocardial Ischaemia National Audit Project (MINAP) database for the months of August and September 2020. HbA1c and eGFR results were gathered from the hospital electronic biochemistry database while diabetic medication was recorded from the British Cardiovascular Interventional Society (BCIS) discharge letter.

Results

Forty-two patients with T2DM admitted between August and September 2020 with ACS and subsequently discharged were audited. In this reaudit, 11 out of 42 (26%) T2DM patients were prescribed gliflozin on discharge. Prescribing of an SGLT2 inhibitor in T2DM patients with CAD has risen.

Patients were divided between ward areas: coronary care unit (CCU) versus cardiology ward admission (Table 1). The CCU group had a higher percentage of patients, 37%, prescribed an SGLT2 inhibitor compared with 17% of patients in the cardiology ward category.

View this table:
  • View inline
  • View popup
Table 1.

Data for patients in our cohort

The main reason for this difference is that all CCU patients are reviewed daily by cardiology consultants, while ward patients are generally looked after by junior doctors and specialty interventional nurses. Although a clinical protocol is available, junior doctors and specialty interventional nurses were cautious in integrating SGLT2 inhibitor into take-home medication.

Conclusion

SGLT2 inhibitor is proven to have mortality benefits in patients with CAD and T2DM. Our clinical protocol was effective in increasing numbers of patients discharged on an SGLT2 inhibitor. To improve this further, we have instigated cardiologist specialist nurse prescribing of SGLT2 inhibitor into daily practice. In addition, we enforced the SGLT2 inhibitor pathway during the junior doctors' and CCU nurses' meeting. We aim to reaudit after 1 year.

  • © Royal College of Physicians 2022. All rights reserved.

Reference

  1. ↵
    1. Zinman B
    , Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Evaluation of clinical practice regarding SGLT2 inhibitor use in patients with type 2 diabetes mellitus and established coronary artery disease in James Cook University Hospital
Ching Khai Ho, Andrew Turley, Mark Hammonds
Clinical Medicine Jul 2022, 22 (Suppl 4) 88-89; DOI: 10.7861/clinmed.22-4-s88

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of clinical practice regarding SGLT2 inhibitor use in patients with type 2 diabetes mellitus and established coronary artery disease in James Cook University Hospital
Ching Khai Ho, Andrew Turley, Mark Hammonds
Clinical Medicine Jul 2022, 22 (Suppl 4) 88-89; DOI: 10.7861/clinmed.22-4-s88
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Objective
    • Methods
    • Results
    • Conclusion
    • Reference
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Reducing anti-cholinergic burden in older patients
  • Implementation of decompensated cirrhosis discharge bundle: a university hospital experience
  • Trends in rates of complications and adverse outcomes in diabetic ketoacidosis following changes to the Joint British Diabetes Societies' management guidelines
Show more QUALITY IMPROVEMENT AND PATIENT SAFETY

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians